Press "Enter" to skip to content

Advaxis Announces Increasing Focus on Neoantigen-Directed Immunotherapies and Closing of Its Phase 3 AIM2CERV Study – SCNow

admin 0

Advaxis Announces Increasing Focus on Neoantigen-Directed Immunotherapies and Closing of Its Phase 3 AIM2CERV Study  SCNow

PRINCETON, N.J.–(BUSINESS WIRE)–Jun 27, 2019–. Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the discovery, …

“bladder cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *